Nitroxyl (HNO) for treatment of acute heart failure

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Heart failure is characterized by impaired cardiac contractile function.
• Current treatments targeting intracellular calcium (Ca2+) often involve cyclic adenosine monophosphate (cAMP) pathways, leading to adverse effects like arrhythmia and myocardial damage with long-term use.
• Nitroxyl (HNO) donors present an alternative mechanism for improving cardiac function.

Purpose of the Study:

• To investigate the efficacy and mechanism of nitroxyl donors in improving cardiac function.
• To evaluate the potential of nitroxyl donors as a therapeutic strategy for heart failure.

Main Methods:

• Studies in normal and failing dogs, and isolated cardiomyocytes.
• Assessment of fractional shortening and Ca(2+) transients.
• Phase I-IIa clinical trials with the novel nitroxyl donor CXL-1020.

Main Results:

• Nitroxyl donors increased fractional shortening and Ca(2+) transients independently of cAMP/PKA or cGMP/PKG signaling.
• Nitroxyl targets cysteines in excitation-contraction coupling machinery and myofilament proteins, enhancing Ca(2+) handling and sensitivity.
• CXL-1020 administration led to reduced cardiac filling pressures and systemic vascular resistance, alongside increased cardiac output and stroke volume index in clinical trials.

Conclusions:

• Nitroxyl donors enhance cardiac contractility through a novel mechanism involving protein cysteine modification.
• CXL-1020 demonstrates favorable hemodynamic effects, supporting its potential for treating acute decompensated heart failure.
• Nitroxyl donors represent a promising therapeutic avenue for heart failure management, distinct from traditional inotropic agents.